NEUROCRINE BIOSCIENCES INC Accounts Payable and Other Accrued Liabilities, Current
NEUROCRINE BIOSCIENCES INC (NBIX) had Accounts Payable and Other Accrued Liabilities, Current of $142.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-07-31
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $142.00M.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $120.00M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $104.90M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $119.90M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current | Accounts Payable and Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $142.00M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $120.00M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $104.90M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $119.90M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $104.60M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $110.00M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $99.90M 10-K · filed 2026-02-11 | $110.00M 10-K · filed 2025-02-10 |
| 2024-09-30 | $95.70M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $107.20M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $87.30M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $133.30M 10-K · filed 2025-02-10 | $108.90M 10-K · filed 2024-02-09 |
| 2023-09-30 | $93.80M 10-Q · filed 2023-10-31 | |
| 2022-12-31 | $67.30M 10-K · filed 2024-02-09 | $76.30M 10-K · filed 2023-02-09 |
| 2021-12-31 | $51.50M 10-K · filed 2023-02-09 | |
| 2020-12-31 | $39.40M 10-K · filed 2022-02-11 | |
| 2019-12-31 | $41.40M 10-K · filed 2021-02-05 | $46.21M 10-K · filed 2020-02-07 |
| 2018-12-31 | $38.38M 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |